• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of thoraxThoraxVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Thorax. Nov 2005; 60(11): 925–931.
Published online Jul 29, 2005. doi:  10.1136/thx.2005.040527
PMCID: PMC1747235

Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease


Background: Patients with chronic obstructive pulmonary disease (COPD) often present with severe acute exacerbations requiring hospital treatment. However, little is known about the prognostic consequences of these exacerbations. A study was undertaken to investigate whether severe acute exacerbations of COPD exert a direct effect on mortality.

Methods: Multivariate techniques were used to analyse the prognostic influence of acute exacerbations of COPD treated in hospital (visits to the emergency service and admissions), patient age, smoking, body mass index, co-morbidity, long term oxygen therapy, forced spirometric parameters, and arterial blood gas tensions in a prospective cohort of 304 men with COPD followed up for 5 years. The mean (SD) age of the patients was 71 (9) years and forced expiratory volume in 1 second was 46 (17)%.

Results: Only older age (hazard ratio (HR) 5.28, 95% CI 1.75 to 15.93), arterial carbon dioxide tension (HR 1.07, 95% CI 1.02 to 1.12), and acute exacerbations of COPD were found to be independent indicators of a poor prognosis. The patients with the greatest mortality risk were those with three or more acute COPD exacerbations (HR 4.13, 95% CI 1.80 to 9.41).

Conclusions: This study shows for the first time that severe acute exacerbations of COPD have an independent negative impact on patient prognosis. Mortality increases with the frequency of severe exacerbations, particularly if these require admission to hospital.

Full Text

The Full Text of this article is available as a PDF (93K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997 May 3;349(9061):1269–1276. [PubMed]
  • Burrows B, Earle RH. Prediction of survival in patients with chronic airway obstruction. Am Rev Respir Dis. 1969 Jun;99(6):865–871. [PubMed]
  • Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1986 Jan;133(1):14–20. [PubMed]
  • Antonelli Incalzi R, Fuso L, De Rosa M, Forastiere F, Rapiti E, Nardecchia B, Pistelli R. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J. 1997 Dec;10(12):2794–2800. [PubMed]
  • Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A, Charpentier C, Kessler R. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest. 1995 May;107(5):1193–1198. [PubMed]
  • Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999 Dec;160(6):1856–1861. [PubMed]
  • Nishimura Koichi, Izumi Takateru, Tsukino Mitsuhiro, Oga Toru. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002 May;121(5):1434–1440. [PubMed]
  • Domingo-Salvany Antònia, Lamarca Rosa, Ferrer Montserrat, Garcia-Aymerich Judith, Alonso Jordi, Félez Miquel, Khalaf Ahmad, Marrades Ramon M, Monsó Eduard, Serra-Batlles Joan, et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002 Sep 1;166(5):680–685. [PubMed]
  • Oga Toru, Nishimura Koichi, Tsukino Mitsuhiro, Sato Susumu, Hajiro Takashi. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med. 2003 Feb 15;167(4):544–549. [PubMed]
  • Celli Bartolome R, Cote Claudia G, Marin Jose M, Casanova Ciro, Montes de Oca Maria, Mendez Reina A, Pinto Plata Victor, Cabral Howard J. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004 Mar 4;350(10):1005–1012. [PubMed]
  • Miravitlles M, Mayordomo C, Artés M, Sánchez-Agudo L, Nicolau F, Segú JL. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Estudio Observacional de la Limitación Obstructiva al Flujo aEreo. Respir Med. 1999 Mar;93(3):173–179. [PubMed]
  • Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1418–1422. [PubMed]
  • Soler J, Sánchez L, Latorre M, Alamar J, Román P, Perpiñ M. Impacto asistencial hospitalario de la EPOC. Peso específico del paciente con EPOC de alto consumo sanitario. Arch Bronconeumol. 2001 Oct;37(9):375–381. [PubMed]
  • Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest. 2000 Nov;118(5):1278–1285. [PubMed]
  • Connors AF, Jr, Dawson NV, Thomas C, Harrell FE, Jr, Desbiens N, Fulkerson WJ, Kussin P, Bellamy P, Goldman L, Knaus WA. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments) Am J Respir Crit Care Med. 1996 Oct;154(4 Pt 1):959–967. [PubMed]
  • Almagro Pedro, Calbo Esther, Ochoa de Echagüen Anna, Barreiro Bienvenido, Quintana Salvador, Heredia José L, Garau Javier. Mortality after hospitalization for COPD. Chest. 2002 May;121(5):1441–1448. [PubMed]
  • Groenewegen Karin H, Schols Annemie M W J, Wouters Emiel F M. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. 2003 Aug;124(2):459–467. [PubMed]
  • Fuso L, Incalzi RA, Pistelli R, Muzzolon R, Valente S, Pagliari G, Gliozzi F, Ciappi G. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med. 1995 Mar;98(3):272–277. [PubMed]
  • Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. [PubMed]
  • Roca J, Sanchis J, Agusti-Vidal A, Segarra F, Navajas D, Rodriguez-Roisin R, Casan P, Sans S. Spirometric reference values from a Mediterranean population. Bull Eur Physiopathol Respir. 1986 May-Jun;22(3):217–224. [PubMed]
  • Tan MJ, Tan JS, Hamor RH, File TM, Jr, Breiman RF. The radiologic manifestations of Legionnaire's disease. The Ohio Community-Based Pneumonia Incidence Study Group. Chest. 2000 Feb;117(2):398–403. [PubMed]
  • Seneff MG, Wagner DP, Wagner RP, Zimmerman JE, Knaus WA. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA. 1995 Dec 20;274(23):1852–1857. [PubMed]
  • Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002 Oct;57(10):847–852. [PMC free article] [PubMed]
  • Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med. 2001 Aug 1;164(3):358–364. [PubMed]
  • Donaldson GC, Seemungal TAR, Patel IS, Lloyd-Owen SJ, Wilkinson TMA, Wedzicha JA. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J. 2003 Dec;22(6):931–936. [PubMed]
  • Patel IS, Seemungal TAR, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax. 2002 Sep;57(9):759–764. [PMC free article] [PubMed]
  • Wilkinson Tom M A, Patel Irem S, Wilks Mark, Donaldson Gavin C, Wedzicha Jadwiga A. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003 Apr 15;167(8):1090–1095. [PubMed]
  • Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS, Tashkin DP. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):381–390. [PubMed]
  • Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000 May 13;320(7245):1297–1303. [PMC free article] [PubMed]
  • Calverley Peter, Pauwels Romain, Vestbo Jørgen, Jones Paul, Pride Neil, Gulsvik Amund, Anderson Julie, Maden Claire. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003 Feb 8;361(9356):449–456. [PubMed]
  • Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003 May;58(5):399–404. [PMC free article] [PubMed]
  • Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J. 2002 Oct;20(4):819–825. [PubMed]
  • Vestbo J. The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J. 2004 Aug;24(2):206–210. [PubMed]
  • Shepherd Frances A, Rodrigues Pereira José, Ciuleanu Tudor, Tan Eng Huat, Hirsh Vera, Thongprasert Sumitra, Campos Daniel, Maoleekoonpiroj Savitree, Smylie Michael, Martins Renato, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123–132. [PubMed]
  • Tsao Ming-Sound, Sakurada Akira, Cutz Jean-Claude, Zhu Chang-Qi, Kamel-Reid Suzanne, Squire Jeremy, Lorimer Ian, Zhang Tong, Liu Ni, Daneshmand Manijeh, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med. 2005 Jul 14;353(2):133–144. [PubMed]

Articles from Thorax are provided here courtesy of BMJ Group


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...